Karyopharm Therapeutics Inc. this week said it plans to put its XPO1 inhibitor Xpovio to the test against the novel coronavirus. In a press release, the company said the drug has already seen positive preclinical activity against several other respiratory viruses. For the treatment of relapsed or refractory multiple myeloma, Xpovio holds preferred status for just 2% of covered lives, growing to 7% with prior authorization and/or step therapy. Xpovio is not covered or not listed for 21% of insured lives.
SOURCE: MMIT Analytics, as of 4/8/20